Mentholatum Vapor Max Ointment
NDC Package 10742-1064-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Mentholatum Vapor Max (camphor, eucalyptus oil, menthol) ointment is see important warnings under "When using this product"adults and children 2 years and over:rub a thick layer on the throat and chest for cough, or rub on sore, aching muscles or jointscover with a warm, dry cloth if desiredclothing should be left loose about the throat and chest to help vapors reach the nose and mouthuse up to 3 times daily, or as directed by a doctorchildren under 2 years of age: Ask a doctor. This formulation utilizes a ointment delivery system. Marketed by The Mentholatum Company, this product is identified by NDC 10742-1064 and is authorized under FDA application M017.

Identification & Billing

NDC Package Code
10742-1064-1
Package Description
1 JAR in 1 CARTON / 28 g in 1 JAR
Product Code
10742-1064
11-Digit Billing Format
10742106401

Clinical Specifications

Proprietary Name
Mentholatum Vapor Max
Non-Proprietary Name
Camphor, Eucalyptus Oil, Menthol
Substance Name
Camphor, (-)-; Eucalyptus Oil; Menthol
Dosage Form
Ointment - A semisolid3 dosage form, usually containing <20% water and volatiles5 and >50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Usage Information
See important warnings under "When using this product"adults and children 2 years and over:rub a thick layer on the throat and chest for cough, or rub on sore, aching muscles or jointscover with a warm, dry cloth if desiredclothing should be left loose about the throat and chest to help vapors reach the nose and mouthuse up to 3 times daily, or as directed by a doctorchildren under 2 years of age: Ask a doctor

Regulatory & Marketing

Labeler Name
The Mentholatum Company
Product Type
Human Otc Drug
FDA Application #
M017
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
08-15-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10742-1064-1 identifies a specific commercial package of 1 jar in 1 carton / 28 g in 1 jar of Mentholatum Vapor Max, a human over the counter drug labeled by The Mentholatum Company. This ointment is formulated for topical use and contains camphor, (-)-; eucalyptus oil; menthol as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by The Mentholatum Company on August 15, 2025. The current certification is valid through December 31, 2027.

How is this The Mentholatum Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10742106401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
10742-1064-1
11-Digit CMS (5-4-2)
10742-1064-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.